Pharmacyclics is ending the year with a bang. In the biggest phase II deal of 2011, the California company signed rights to its blood-cancer drug PCI-32765 to Johnson & Johnson for a huge $150m upfront, a deal that executives say will secure sufficient funding to take the Bruton’s tyrosine kinase (Btk) inhibitor to market without tapping investors.The global pact could represent a big win in the long term as well, as it entitles Pharmacyclics to half the profits generated by the partnership. Shares, however, were down 12% to $12.89 in early trading today. After more than doubling in price this year and with the anticipated licensing deal completed major catalysts are now more than a year away, while any hope of a trade sale has been erased (Trial success opening doors for Pharmacyclics, June 15, 2011).
This content is written, edited and published by EP Vantage and is distributed by EvaluatePharma Ltd. All queries regarding the content should be directed to: email@example.com
EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.
Drawing on EvaluatePharma, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.
Terms & Conditions